Sangamo BioSciences | SGMO - Srodki Pieniężne I Ekwiwalent





Srodki Pieniężne I Ekwiwalent Zmiana Data
Alaunos Therapeutics USD 354K 1.03M 2026-03
Alnylam Pharmaceuticals USD 1.71B 53.53M 2026-03
Alterity Therapeutics Limited AUD 15.77M 9.56M 2023-06
Amgen USD 12.04B 2.91B 2026-03
Bayer EUR 6.67B 774M 2025-12
BioCryst Pharmaceuticals USD 171.59M 164.32M 2026-03
Biogen USD 3.38B 374.2M 2026-03
BioMarin Pharmaceutical USD 2.22B 910.76M 2026-03
Cipla INR 7.96B 39.9M 2025-09
Clal Biotechnology ILS 5.73M 1.71M 2023-12
Compugen USD 90.6M 83.14M 2025-12
CSL USD 2.16B 633M 2025-06
Gilead Sciences USD 7.56B 234M 2025-12
GlaxoSmithKline GBP 3.44B 292M 2026-03
Grifols EUR 979.78M 334.84M 2024-12
Ionis Pharmaceuticals USD 1.92B 758M 2026-03
J&J USD 21.69B 1.98B 2026-03
Karyopharm Therapeutics USD 60.54M 22.87M 2025-12
Merck USD 5.33B 9.24B 2026-03
Novartis USD 6.88B 4.56B 2026-03
Omeros USD 1.9M 2.36M 2025-06
Pfizer USD 1.7B 561M 2026-03
Roche Holding CHF 7.55B 579M 2025-06
Sangamo BioSciences USD 38.34M 13.16M 2025-06
Sanofi EUR 7.66B 1.25B 2025-12
Sarepta Therapeutics USD 464.45M 336.83M 2026-03
Tectonic Therapeutic USD 236.89M 16.9M 2026-03
Ultragenyx Pharmaceutical USD 175M 246M 2026-03
Vertex Pharmaceuticals USD 7.25B 638.6M 2026-03